---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009852"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:25:56.393983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics reports Q4 2022 net loss $29.1M; TNG462 gets Fast Track; appoints new R&D President

## Summary
- Net loss of $29.1M in Q4 2022 ($0.33/share) vs $22.0M ($0.25) in Q4 2021; FY2022 net loss $108.2M ($1.23) vs $58.2M ($0.94).
- Cash of $366.1M at Dec 31, 2022 expected to fund operations into 2025.
- FDA granted Fast Track Designation to TNG462, a next-gen MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers.
- Adam Crystal, M.D., Ph.D. appointed President of Research and Development in February 2023.
- Upcoming: TNG908 proof-of-mechanism update Q2 2023; IND filings for TNG260 (H1 2023) and TNG348 (mid-2023).

## SEC filing metadata
- accession: 0000950170-23-009852
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/0000950170-23-009852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009852
- JSON: https://secwatch.observer/filing/0000950170-23-009852.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009852.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/0000950170-23-009852-index.htm
- Earnings Releases
  Tango Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $6.4 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $6.4 million
  - Result: reported results
  source text: Collaboration revenue was $6.4 million for the three months ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/0000950170-23-009852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.